Arkansas Medicaid spending on GLP-1 drugs

How much did Arkansas Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $18.9 million for GLP-1 drugs paid through Arkansas Medicaid in 2025, across at least 24,039 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 111 rows of 279, so these figures are floors.

Pharmacies were reimbursed at least $7.5 million for GLP-1 drugs paid through Arkansas Medicaid in 2026 (quarter 1 only, as posted so far), across at least 8,394 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 28 rows of 74, so these figures are floors.

By year and ingredient

2020SuppressedNo data$2,975,568at least $106,828at least $621,101SuppressedSuppressedat least $3,703,497
2021at least $34,602No data$4,497,201at least $127,713at least $298,411SuppressedSuppressedat least $4,957,927
2022at least $272,253at least $26,906$7,837,442at least $301,340at least $114,729SuppressedSuppressedat least $8,552,669
2023at least $920,301at least $180,506at least $13,406,478at least $537,763at least $488,105SuppressedSuppressedat least $15,533,153
2024at least $2,218,358at least $724,778at least $9,387,732at least $449,260at least $1,301,727SuppressedSuppressedat least $14,081,854
2025at least $4,659,779at least $1,985,112at least $5,952,837at least $5,840,148at least $433,125SuppressedNo dataat least $18,871,001
2026 (Q1)at least $1,448,380at least $888,742at least $1,202,396$3,946,407SuppressedNo dataNo dataat least $7,485,924

By product, 2025

Ozempic$4,405,9314,5110 of 24
Rybelsusat least $10,887at least 1123 of 24
Wegovyat least $242,960at least 18525 of 35
Mounjaroat least $1,985,112at least 1,8732 of 48
ZepboundSuppressedSuppressed25 of 25
Liraglutide (generic name listing)at least $3,498,120at least 7,02012 of 49
SaxendaSuppressedSuppressed2 of 2
Victoza$2,454,7173,8610 of 16
Trulicityat least $5,840,148at least 6,0533 of 30
Bydureonat least $14,272at least 192 of 3
Byettaat least $418,853at least 5068 of 14
Exenatide (generic name listing)SuppressedSuppressed6 of 6
SoliquaSuppressedSuppressed3 of 3

By quarter, 2025

Q1 2025at least $3,500,402at least 4,74922 of 61
Q2 2025at least $3,782,874at least 5,19529 of 70
Q3 2025at least $5,276,031at least 6,65132 of 74
Q4 2025at least $6,311,694at least 7,44428 of 74

By quarter, 2026 (posted so far)

Q1 2026at least $7,485,924at least 8,39428 of 74

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.